SCHEDULE 13G: BlackRock Discloses 6.9% Passive Stake in CRISPR Therapeutics AG

BlackRock, Inc. has filed a Schedule 13G, reporting a 6.9% beneficial ownership stake in CRISPR Therapeutics AG as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 5,932,433 shares of Common Stock in CRISPR Therapeutics AG.
• This ownership represents 6.9% of the class of securities.
• BlackRock holds sole voting power over 5,766,693 shares and sole dispositive power over 5,932,433 shares.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• BlackRock, Inc. is a Delaware-organized entity with its principal business office at 50 Hudson Yards, New York, NY 10001.
• The beneficial ownership is held by various BlackRock business units and subsidiaries, including BlackRock Investment Management, LLC, which beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant passive institutional stake, indicating continued investment by a major asset manager. It is neutral to slightly positive as it confirms a large institutional holder's position.

Future Outlook

Not applicable, as this filing is a disclosure of past beneficial ownership and does not provide forward-looking statements or guidance from the issuer.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates that BlackRock, a major institutional asset manager, holds a significant passive stake in CRISPR Therapeutics AG. Such filings are routine disclosures by large investors when their ownership crosses certain thresholds (typically 5% for passive investors), providing transparency on institutional holdings within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.

Key Dates

Keywords

BlackRock, CRISPR Therapeutics AG, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Stake